Skip to main content

Bendeka Disease Interactions

There are 4 disease interactions with Bendeka (bendamustine).

Major

Bendamustine (applies to Bendeka) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Bendamustine injection should be used with caution in patients with hepatic impairment. Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.

References

  1. (2008) "Product Information. Treanda (bendamustine)." Cephalon Inc
Major

Bendamustine (applies to Bendeka) renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Bendamustine injection should be used with caution in patients with mild or moderate renal impairment. Bendamustine injection should not be used in patients with CrCL < 40 mL/min.

References

  1. (2008) "Product Information. Treanda (bendamustine)." Cephalon Inc
Moderate

Bendamustine (applies to Bendeka) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Infection - Bacterial/Fungal/Protozoal/Viral

Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.

References

  1. (2008) "Product Information. Treanda (bendamustine)." Cephalon Inc
  2. (2016) "Product Information. Bendeka (bendamustine)." Teva Pharmaceuticals USA
Moderate

Bendamustine (applies to Bendeka) myelosuppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Adult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death. Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections. Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.

References

  1. (2008) "Product Information. Treanda (bendamustine)." Cephalon Inc

Bendeka drug interactions

There are 276 drug interactions with Bendeka (bendamustine).

Bendeka alcohol/food interactions

There is 1 alcohol/food interaction with Bendeka (bendamustine).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.